Q-omics provides the consensus-scored PA2G4P1 profile across patient tissues and cancer cell-line models. PA2G4P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PA2G4P1 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, PA2G4P1 RNA expression shows 6,963 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight KICH, and COAD as cancer lineages where PA2G4P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PA2G4P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PA2G4P1 survival associations across molecular data types. PA2G4P1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PA2G4P1 RNA expression–survival associations across cancer types. High PA2G4P1 expression shows unfavorable associations in KICH, ACC, LUAD, LIHC, CESC and COAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PA2G4P1 RNA expression.
This table summarizes PA2G4P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PA2G4P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PA2G4P1 shows higher tumor expression in COAD, KIRC, LUAD, LIHC, STAD and LUSC. The COAD box plot shows higher PA2G4P1 RNA expression in tumor versus normal tissue (log2 FC = +0.397, t-test p < 0.001).
This table shows molecular features associated with PA2G4P1 in patient tissues and cancer cell lines. In patient samples, PA2G4P1 shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set.
